Infinity Pharmaceuticals, Inc. (INFI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Infinity Pharmaceuticals, Inc. (INFI) Healthcare & Pipeline Overview

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer therapies, primarily through its IPI-549 immuno-oncology product candidate. With strategic alliances and a focus on phosphoinositide-3-kinase-gamma inhibition, the company aims to address unmet needs in metastatic triple negative breast cancer, urothelial cancer, and solid tumors.

What Is the Investment Thesis for INFI?

Infinity Pharmaceuticals' investment thesis centers on the potential of IPI-549, its lead immuno-oncology product candidate, to address unmet needs in cancer treatment. The ongoing Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer, along with Phase 1/1b trials for solid tumors, represent key value drivers. Success in these trials could lead to significant market opportunities. The company's strategic alliances with Intellikine, Verastem, PellePharm, Arcus Biosciences, F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company provide additional avenues for growth and potential revenue streams. However, the company's negative profit margin of -1711.1% and reliance on clinical trial outcomes present significant risks. Positive data readouts and successful commercialization of IPI-549 are crucial for realizing the investment thesis.

Based on FMP financials and quantitative analysis

INFI Key Highlights

IPI-549 is in Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer, indicating potential for near-term value creation.

• Strategic alliances with Intellikine, Verastem, and PellePharm provide access to diverse research and development capabilities.
• Collaboration agreements with Arcus Biosciences, F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company validate the company's technology and provide potential for future partnerships.
• Gross margin of 39.7% indicates potential for profitability upon successful commercialization of IPI-549.
• The company's small size, with only 30 employees, allows for agility and focused execution of its clinical programs.

Who Are INFI's Competitors?

INFI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INFI's Key Strengths?

Novel immuno-oncology agent (IPI-549).

• Strategic alliances with multiple companies.
• Clinical-stage product pipeline.
• Experienced management team.

What Are INFI's Weaknesses?

Limited financial resources.

• Reliance on clinical trial outcomes.
• High research and development costs.
• Negative profit margin.

What Could Drive INFI Stock Higher?

INFI catalyst: Data readouts from Phase 2 clinical trials of IPI-549 in metastatic triple negative breast cancer and urothelial cancer.

• Potential regulatory approval of IPI-549.
• Strategic alliances and collaborations with other biotechnology companies.
• Expansion of the product pipeline through research and development efforts.

What Are the Key Risks for INFI?

Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results.
• Regulatory hurdles and delays.
• Competition from other biotechnology companies.
• Limited financial resources.
• Patent expirations.

What Are the Growth Opportunities for INFI?

• Expansion into New Therapeutic Areas: Infinity Pharmaceuticals has the opportunity to expand its pipeline beyond IPI-549 by exploring new therapeutic areas within oncology. By leveraging its expertise in PI3K-gamma inhibition, the company could develop novel therapies for other cancer types with unmet needs. The global oncology market is projected to reach $286.6 billion by 2030, providing a significant opportunity for growth. Timeline: 3-5 years.
• Strategic Partnerships and Acquisitions: Infinity Pharmaceuticals can pursue strategic partnerships and acquisitions to expand its pipeline and access new technologies. Collaborating with other biotechnology companies or acquiring promising assets could accelerate the development of new cancer therapies and diversify the company's portfolio. The market for mergers and acquisitions in the biotechnology industry is robust, with numerous opportunities for value creation. Timeline: Ongoing.
• Commercialization of IPI-549: The successful commercialization of IPI-549 represents a significant growth opportunity for Infinity Pharmaceuticals. If the ongoing clinical trials are successful, the company could launch IPI-549 as a treatment for metastatic triple negative breast cancer, urothelial cancer, and solid tumors. The market for these indications is substantial, with significant unmet needs. Timeline: 2-3 years, pending clinical trial results and regulatory approval.
• Development of Combination Therapies: Infinity Pharmaceuticals can explore the development of combination therapies involving IPI-549 and other cancer treatments. Combining IPI-549 with existing chemotherapies or immunotherapies could enhance its efficacy and expand its potential applications. The market for combination therapies in oncology is growing rapidly, driven by the increasing recognition of the benefits of combining different treatment modalities. Timeline: 3-5 years.
• Geographic Expansion: Infinity Pharmaceuticals has the opportunity to expand its geographic reach by commercializing its products in new markets. The company could partner with international distributors or establish its own sales and marketing infrastructure in key regions such as Europe and Asia. The global market for cancer therapies is growing rapidly, with significant opportunities in emerging markets. Timeline: 3-5 years.

What Are INFI's Competitive Advantages?

• Proprietary technology: IPI-549 is a novel immuno-oncology agent with a unique mechanism of action.
• Strategic alliances: Partnerships with Intellikine, Verastem, and PellePharm provide access to diverse research and development capabilities.
• Clinical-stage product pipeline: IPI-549 is in Phase 2 clinical trials, indicating potential for near-term value creation.
• Intellectual property: Patents and other intellectual property protect the company's technology and products.

What Does INFI Do?

Incorporated in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals, Inc. is a biopharmaceutical company committed to discovering and developing innovative medicines for individuals battling cancer. The company's primary focus is on advancing novel therapies that target critical pathways in cancer biology. Their lead product candidate, IPI-549, is an orally administered immuno-oncology agent designed to inhibit the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). IPI-549 is currently undergoing Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer, as well as Phase 1/1b clinical trials for solid tumors. Infinity Pharmaceuticals has established strategic alliances to bolster its research and development efforts. These collaborations include partnerships with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926. The company also has collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company, further expanding its network and resources in the pursuit of innovative cancer treatments. Infinity Pharmaceuticals operates with a team of 30 employees dedicated to advancing its clinical programs and strategic partnerships.

What Products and Services Does INFI Offer?

• Develop novel medicines for people with cancer.
• Focus on immuno-oncology product candidates.
• Inhibit the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma).
• Conduct Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer.
• Conduct Phase 1/1b clinical trials for solid tumors.
• Establish strategic alliances with other biotechnology companies.
• Research, develop, and commercialize pharmaceutical products.

How Does INFI Make Money?

• Develop and commercialize novel cancer therapies.
• Generate revenue through product sales and licensing agreements.
• Collaborate with other biotechnology companies to share research and development costs.
• Out-license intellectual property to generate royalty income.

What Industry Does INFI Operate In?

Infinity Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immuno-oncology market, where IPI-549 is positioned, is experiencing significant growth due to the increasing prevalence of cancer and the demand for innovative therapies. Key trends in the industry include the development of personalized medicine, the use of biomarkers to identify patients who are most likely to respond to treatment, and the increasing adoption of combination therapies. Infinity Pharmaceuticals' success depends on its ability to navigate these trends and differentiate itself from competitors by developing effective and safe cancer treatments.

Who Are INFI's Key Customers?

• Patients with cancer.
• Hospitals and oncology clinics.
• Healthcare providers.
• Pharmaceutical companies (through partnerships and licensing agreements).

Company Profile

Infinity Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Seth A. Tasker. INFI has traded publicly since 2000.

How Infinity Pharmaceuticals, Inc. Is Valued

Relative to its peer group, INFI's quantitative score of 56/100 is below the peer average of 69/100.

Infinity Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Infinity Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 15.8% below estimates on average.

INFI Financials

INFI Latest News

No recent news available for INFI.

INFI Analyst Consensus

INFI MoonshotScore

INFI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources